NCT05182034 is a Phase 2 clinical trial of SMUP-IA-01(low dose) in Knee Osteoarthritis, sponsored by Medipost Co Ltd..

Who is sponsoring NCT05182034?

NCT05182034 is sponsored by Medipost Co Ltd..

What drugs are being tested in NCT05182034?

Interventions in NCT05182034: SMUP-IA-01(low dose), SMUP-IA-01(mid dose), Active Control Group Sodium chloride.

What condition does NCT05182034 study?

NCT05182034 studies Knee Osteoarthritis.

Is NCT05182034 still recruiting?

NCT05182034 is currently completed. Last updated 5 February 2025.

Last reviewed 2025-02-05 · How we verify

NCT05182034

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial to Evaluate Efficacy and Safety of SMUP-IA-01 in Patients With Knee Osteoarthritis

Completed Phase 2 Last updated 5 February 2025

What this trial tests

Phase 2 trial testing SMUP-IA-01(low dose) in Knee Osteoarthritis in 94 participants. Completed in 17 October 2023.

Timeline

24 February 2022

Primary endpoint
17 October 2023

17 October 2023

Quick facts

Lead sponsor	Medipost Co Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	94
Start date	24 February 2022
Primary completion	17 October 2023
Estimated completion	17 October 2023
Sites	5 locations across South Korea

Drugs / interventions tested

SMUP-IA-01(low dose) — full drug profile →
SMUP-IA-01(mid dose) — full drug profile →
Active Control Group Sodium chloride

Conditions studied

Knee Osteoarthritis — all drugs for Knee Osteoarthritis →

Sponsor

Medipost Co Ltd. — full company profile →

Who can join

19 and older, any sex, with Knee Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial is for patients who have been diagnosed with Kellgren-Lawrence (K\&L) Grade 2 or 3 knee osteoarthritis on radiographic examination. Only subjects who voluntarily agree to participate by filling out the written Informed Consent document will undergo screening for subject selection (inclusion/exclusion) criteria, at which time the severity of OA in each knee will be used to determined which knee will be treated (index knee - i.e., the more severely affected knee), and enroll in this study.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Knee osteoarthritis: disease burden, available treatments, and emerging options.
Langworthy M, Dasa V, Spitzer AI. · · 2024 · cited 37× · PMID 39290780 · DOI 10.1177/1759720x241273009
Stem cell injections for osteoarthritis of the knee.
Whittle SL, Johnston RV, McDonald S, Worthley D, et al · · 2025 · cited 11× · PMID 40169165 · DOI 10.1002/14651858.cd013342.pub2

Verify or expand the search:

Other recruiting trials for Knee Osteoarthritis

Currently open trials in the same condition.

NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
NCT05823727 — Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing Afte · NA · recruiting
NCT07370480 — Knee Osteoarthritis and Thermal Spa Treatment · NA · recruiting
NCT07507175 — Gastrocnemius Myofascial Release in Females With Knee Osteoarthritis · NA · recruiting
NCT07386600 — Dexamethasone vs Dexmedetomidine for iPACK + ACB in TKA · NA · recruiting

Other Medipost Co Ltd. trials

Trials by the same sponsor.

NCT06798727 — Evaluation Safety and Explore Efficacy Long-term Follow-up Study on Subjects Receiving SMUP-IA-01 or Active Control · Phase 2 · active not recruiting
NCT04037345 — Evaluate Safety and Explore Efficacy of SMUP-IA-01 in Patients With Knee Osteoarthritis · Phase 1 · completed
NCT04003857 — Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial · Phase 2 · active not recruiting
NCT03676400 — Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia · NA · completed
NCT03392467 — PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05182034 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medipost Co Ltd.
Last refreshed: 5 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05182034.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing